Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B. AbbVie is setting up a shot to buy Kestrel Therapeutics down the line. The exclusive…
AbbVie secured an option to acquire Kestrel Therapeutics at an agreed-upon price, funding the KST-6051 pan-KRAS program in early human testing; max deal value…
Kestrel Therapeutics dosed the first patient in FALCON, its Phase 1, open-label dose-escalation and expansion study of KST-6051. Total potential consideration,…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
AbbVie entered a warrant agreement with Kestrel funding KST-6051 development plus an exclusive option to acquire Kestrel based on defined development/regulatory milestones; total deal value up to $1.45B across upfront, exercise, and downstream milestone payments. First patient dosed in Phase 1 FALCON trial concurrently announced.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Kestrel Therapeutics, Inc. (this deal) | 2026 | $1.4B | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2026 deals · AbbVie Inc. deals · Oncology deals